Coagulation Factor Deficiency Market Size, Share, Growth, Trends, and Global Industry Analysis: By Deficiency Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, and Others), By Product Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologics, Desmopressin, and Others), By End Users (Hospitals, Clinics, Homecare, Others) and Region Forecast 2020-2031

Coagulation Factor Deficiency Market size was valued at US$ 16.2 billion in 2024 and is expected to reach US$ 25.5 billion by 2031, growing at a significant CAGR of 6.7% from 2025-2031. Coagulation factor deficiency is a rare condition that affects the blood’s ability to clot normally and can be caused by genetic mutations, acquired disease, or medications. Based on the treatment type, enzyme replacement therapy is anticipated to dominate the market share over the forecast period.

According to the World Federation of Hemophilia, there were around 1,95,263 people worldwide who had been diagnosed with hemophilia and 80,302 people who had been diagnosed with von Willebrand disease in 2019. The increasing incidences of blood-related disorders and increasing awareness of the disease will act as the coagulation   market growth driver. However, the high cost of treatment would be the lagging factor for the market. Unmet needs for bleeding disorders, the evolving healthcare infrastructure, and increasing disposable incomes will be opportunities for market expansion.

Key Developments:

• In Nov 2022, The US FDA approved CSL Behring’s Hemgenix (Etranacongene Dezaparvovec), an adeno-associated virus vector-based gene therapy, for the treatment of adults with hemophilia A and B.
• In Feb 2023, Sanofi received approval of the US FDA for Efanesoctocog alfa, a high-sustained factor VIII replacement therapy, for the treatment of hemophilia A in adults.